BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis

Nature

Volumn 527, Issue 7577, 2015, Pages 192-197

  Canver, Matthew C ^a   Smith, Elenoe C ^a   Sher, Falak ^a   Pinello, Luca ^b   Sanjana, Neville E ^c   Shalem, Ophir ^c   Chen, Diane D ^a   Schupp, Patrick G ^a   Vinjamur, Divya S ^a   Garcia, Sara P ^b   Luc, Sidinh ^a   Kurita, Ryo ^d   Nakamura, Yukio ^d,e   Fujiwara, Yuko ^a,f   Maeda, Takahiro ^g   Yuan, Guo Cheng ^b   Zhang, Feng ^c   Orkin, Stuart H ^a,f   Bauer, Daniel E ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d RIKEN BIORESOURCE CENTER   (Japan)

^e UNIVERSITY OF TSUKUBA   (Japan)

^f HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCL11A PROTEIN; CRISPR ASSOCIATED PROTEIN; CRISPR ASSOCIATED PROTEIN 9; HEMOGLOBIN; HEMOGLOBIN F; HEMOGLOBIN GAMMA CHAIN; PROTEIN; UNCLASSIFIED DRUG; BCL11A PROTEIN, HUMAN; BCL11A PROTEIN, MOUSE; CARRIER PROTEIN; GUIDE RNA; NUCLEAR PROTEIN;

BLOOD; GENE EXPRESSION; GENETIC VARIATION; GENOMICS; IN SITU MEASUREMENT; MUTATION; PROTEIN; RODENT; VULNERABILITY;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; EMBRYO; ENHANCER REGION; ERYTHROBLAST; ERYTHROID CELL; EXON; FEMALE; GENE EXPRESSION; GENETIC VARIABILITY; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOUSE; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; TRANSGENICS; ANIMAL; ANTIBODY SPECIFICITY; CELL CULTURE; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; CRISPR CAS SYSTEM; GENETIC ENGINEERING; GENETICS; GENOME; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; REPRODUCIBILITY; SPECIES DIFFERENCE;

PRIMATES;

ANIMALS; BASE SEQUENCE; CARRIER PROTEINS; CELLS, CULTURED; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS; CRISPR-ASSOCIATED PROTEINS; CRISPR-CAS SYSTEMS; ENHANCER ELEMENTS, GENETIC; ERYTHROBLASTS; FETAL HEMOGLOBIN; GENETIC ENGINEERING; GENOME; HUMANS; MICE; MOLECULAR SEQUENCE DATA; MUTAGENESIS; NUCLEAR PROTEINS; ORGAN SPECIFICITY; REPRODUCIBILITY OF RESULTS; RNA, GUIDE; SPECIES SPECIFICITY;

EID: 84946925193     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature15521     Document Type: Article

References (60)

1. Banerji, J., Rusconi, S. & Schaffner, W. Expression of a β-globin gene is enhanced by remote SV40 DNA sequences. Cell 27, 299-308 (1981).
2. Visel, A. et al. ChIP-seq accurately predicts tissue-specific activity of enhancers. Nature 457, 854-858 (2009).
3. Thurman, R. E. et al. The accessible chromatin landscape of the human genome. Nature 488, 75-82 (2012).
4. Andersson, R. et al. An atlas of active enhancers across human cell types and tissues. Nature 507, 455-461 (2014).
5. Heintzman, N. D. et al. Histone modifications at human enhancers reflect global cell-type-specific gene expression. Nature 459, 108-112 (2009).
6. Creyghton, M. P. et al. Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc. Natl Acad. Sci. USA 107, 21931-21936 (2010).
7. Xu, J. et al. Combinatorial assembly of developmental stage-specific enhancers controls gene expression programs during human erythropoiesis. Dev. Cell 23, 796-811 (2012).
8. Ernst, J. et al. Mapping and analysis of chromatin state dynamics in nine human cell types. Nature 473, 43-49 (2011).
9. Parker, S. C. J. et al. Chromatin stretch enhancer states drive cell-specific gene regulation and harbor human disease risk variants. Proc. Natl Acad. Sci. USA 110, 17921-17926 (2013).
10. Whyte, W. A. et al. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell 153, 307-319 (2013).
11. Paul, D. S. et al. Maps of open chromatin guide the functional follow-up of genome-wide association signals: Application to hematological traits. PLoS Genet. 7, e1002139 (2011).
12. Maurano, M. T. et al. Systematic localization of common disease-associated variation in regulatory DNA. Science 337, 1190-1195 (2012).
13. Hardison, R. C. Variable evolutionary signatures at the heart of enhancers. Nature Genet. 42, 734-735 (2010).
14. Vierstra, J. et al. Mouse regulatory DNA landscapes reveal global principles of cis-regulatory evolution. Science 346, 1007-1012 (2014).
15. Villar, D. et al. Enhancer evolution across 20 mammalian species. Cell 160, 554-566 (2015).
16. Pennacchio, L. A. et al. In vivo enhancer analysis of human conserved non-coding sequences. Nature 444, 499-502 (2006).
17. Melnikov, A. et al. Systematic dissection and optimization of inducible enhancers in human cells using a massively parallel reporter assay. Nature Biotechnol. 30, 271-277 (2012).
18. Patwardhan, R. P. et al. Massively parallel functional dissection of mammalian enhancers in vivo. Nature Biotechnol. 30, 265-270 (2012).
19. Sexton, T. & Cavalli, G. The role of chromosome domains in shaping the functional genome. Cell 160, 1049-1059 (2015).
20. Bender, M., Bulger, M., Close, J. & Groudine, M. β-globin gene switching and DNase I sensitivity of the endogenous β-globin locus in mice do not require the locus control region. Mol. Cell 5, 387-393 (2000).
21. Johnson, K. D. et al. Cis-element mutated in GATA2-dependent immunodeficiency governs hematopoiesis and vascular integrity. J. Clin. Invest. 122, 3692-3704 (2012).
22. Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819-823 (2013).
23. Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823-826 (2013).
24. Wang, T., Wei, J. J., Sabatini, D. M. & Lander, E. S. Genetic screens in human cells using the CRISPR-Cas9 system. Science 343, 80-84 (2014).
25. Shalem, O. et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343, 84-87 (2014).
26. Koike-Yusa, H., Li, Y., Tan, E.-P., Velasco-Herrera, M. D. C. & Yusa, K. Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library. Nature Biotechnol. 32, 267-273 (2014).
27. Zhou, Y. et al. High-throughput screening of a CRISPR/Cas9 library for functional genomics in human cells. Nature 509, 487-491 (2014).
28. Bauer, D. E. et al. An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin level. Science 342, 253-257 (2013).
29. Gröschel, S. et al. A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in Leukemia. Cell 157, 369-381 (2014).
30. Mansour, M. R. et al. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science 346, 1373-1377 (2014).
31. Sankaran, V. G. et al. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science 322, 1839-1842 (2008).
32. Sankaran, V. G. et al. Developmental and species-divergent globin switching are driven by BCL11A. Nature 460, 1093-1097 (2009).
33. Xu, J. et al. Correction of sickle cell disease in adult mice by interference with fetal hemoglobin silencing. Science 334, 993-996 (2011).
34. Kurita, R. et al. Establishment of immortalized human erythroid progenitor cell lines able to produce enucleated red blood cells. PLoS ONE 8, e59890 (2013).
35. Hardison, R. C. & Blobel, G. A. GWAS to therapy by genome edits? Science 342, 206-207 (2013).
36. Canver, M. C. et al. Characterization of genomic deletion efficiency mediated by clusted regularly interspaced palindromic repeats (CRISPR)/Cas9 nuclease system in mammalian cells. J. Biol. Chem. 289, 21312-21324 (2014).
37. Mandal, P. K. et al. Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9. Cell Stem Cell 15, 643-652 (2014).
38. Ran, F. A. et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 154, 1380-1389 (2013).
39. Hsu, P. D. et al. DNA targeting specificity of RNA-guided Cas9 nucleases. Nature Biotechnol. 31, 827-832 (2013).
40. Liu, P. et al. Bcl11a is essential for normal lymphoid development. Nature Immunol. 4, 525-532 (2003).
41. John, A. et al. Bcl11a is required for neuronal morphogenesis and sensory circuit formation in dorsal spinal cord development. Development 139, 1831-1841 (2012).
42. Yu, Y. et al. Bcl11a is essential for lymphoid development and negatively regulates p53. J. Exp. Med. 209, 2467-2483 (2012).
43. Porcu, B. S. et al. The human β globin locus introduced by YAC transfer exhibits a specific and reproducible pattern of developmental regulation in transgenic mice. Blood 90, 4602-4609 (1997).
44. Ran, F. A. et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature 520, 186-191 (2015).
45. Kleinstiver, B. P. et al. Engineered CRISPR-Cas9 nucleases with altered and improved PAM specificities. Nature 523, 481-485 (2015).
46. Esvelt, K. M. et al. Orthogonal Cas9 proteins for RNA-guided gene regulation and editing. Nature Methods 10, 1116-1121 (2013).
47. Findlay, G. M., Boyle, E. A., Hause, R. J., Klein, J. C. & Shendure, J. Saturation editing of genomic regions by multiplex homology-directed repair. Nature 513, 120-123 (2014).
48. Bauer, D. E., Kamran, S. C. & Orkin, S. H. Reawakening fetal hemoglobin: Prospects for new therapies for the beta-globin disorders. Blood 120, 2945-2953 (2012).
49. Basak, A. et al. Persistence of fetal hemoglobin and altered neurodevelopment due to BCL11A deletions. JCI 125, 2363-2368 (2015).
50. Funnell, P. W. et al. 2p15-p16.1 microdeletions encompassing and proximal to BCL11A are associated with elevated HbF in addition to neurologic impairment. Blood 126, 89-93 (2015).
51. Sanjana, N. E., Shalem, O. & Zhang, F. Improved vectors and genome-wide libraries for CRISPR screening. Nature Methods 11, 783-784 (2014).
52. Chen, S. et al. Genome-wide CRISPR screenina mouse model of tumor growth and metastasis. Cell 160, 1246-1260 (2015).
53. Giarratana, M. et al. Proof of principle for transfusion of in vitro generated red blood cells. Blood 118, 5071-5079 (2011).
54. Brinkman, E. K., Chen, T., Amendola, M. & van Steensel, B. Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res. 42, e168 (2014).
55. Kowalczyk, M. S. et al. Intragenic enhancers act as alternative promoters. Mol. Cell 45, 447-458 (2012).
56. Dogan, N. et al. Occupancy by key transcription factors is a more accurate predictor of enhancer activity than histone modifications or chromatin accessibility. Epigenetics Chromatin 8, 16 (2015).
57. Grant, C. E., Bailey, T. L. & Noble, W. S. FIMO: scanning for occurrences of a given motif. Bioinformatics 27, 1017-1018 (2011).
58. Mathelier, A. et al. JASPAR 2014: An extensively expanded and updated open-access database of transcription factor binding profiles. Nucleic Acids Res. 42, 142-147 (2014).
59. Weber, K., Bartsch, U., Stocking, C. & Fehse, B. A multicolor panel of novel lentiviral 'gene ontology' (LeGO) vectors for functional gene analysis. Mol. Ther. 16, 698-706 (2008).
60. Doench, J. G. et al. Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation. Nature Biotechnol. 32, 1262-1267 (2014).